Current Novartis chair Jörg Reinhardt will not stand for re-election in 2025 after a 12-year term of office and will retire as planned.
Keystone / Georgios Kefalas
Change is afoot in the upper echelons of Novartis, with Giovanni Caforio set to be elected as the next chair of its board of directors at the 2025 Annual General Meeting.
He will replace current chair Jörg Reinhardt, who will not stand for re-election in 2025 after a 12-year term of office and will retire as planned.
New chair designate Caforio has spent a large part of his professional career at Bristol Myers Squibb (BMS). He was CEO from May 2015 to November 2023 and served as executive chair from May 2017 to March 2024.
Under his leadership, BMS successfully transformed itself into a global medicines company with strong capabilities in research and development as well as commercialisation, Novartis wrote in a statement on Tuesday.
Caforio was born in Italy and is a trained physician. He holds both Italian and US citizenship, and speaks fluent Italian, French, Spanish, Portuguese, and English.
Adapted from German by DeepL/kp/sb
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
Precious archaeological vases and coins returned to Italian museum
This content was published on
The Italian authorities have recovered over 2,500 precious ancient coins, vases and small sculptures that had been illegally dug up and sold in Switzerland, Eurojust announced on Monday.
PrimeEnergy Cleantech declared bankrupt by Swiss authorities
This content was published on
PrimeEnergy Cleantech has been officially declared bankrupt, the Swiss Official Gazette of Commerce (SOGC) reported on Monday.
This content was published on
The consumption of antibiotics has risen in Switzerland since the Covid-19 pandemic. However, compared to other European countries the Alpine country has one of the lowest levels of antibiotic usage.
Swiss financial watchdog foresees greater uncertainty due to geopolitics
This content was published on
The Swiss financial sector will face greater uncertainty due to the numerous geopolitical conflicts around the world, warns the Swiss Financial Market Supervisory Authority (FINMA).
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharma: Novartis announces job cuts in the development division
This content was published on
In Switzerland, 400 to 440 positions in the company's development division are likely to fall victim to the measures over the next two to three years.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.